Onvansertib + Abiraterone/Prednisone
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 2Enrolling
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 2
Status
Enrolling
Company
About Cardiff Oncology
Cardiff Oncology's mission is to develop novel cancer therapies by leveraging Polo-like kinase 1 (PLK1) inhibition. Its core achievement is advancing its lead asset, onvansertib, into multiple mid-stage clinical trials in combination with standard regimens for difficult-to-treat cancers like metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). The company's strategy is predicated on using onvansertib to target tumor vulnerabilities and overcome resistance to existing therapies, aiming to deliver superior clinical benefit. Cardiff's future is entirely tied to the clinical validation of this combination approach.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |
| Gedatolisib | Celcuity | Phase 3 Planned |